Non-Small Cell Lung Cancer
Advertisement
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
This follows the FDA’s August 2024 move to grant Priority Review for the subcutaneous amivantamab BLA.
A qualitative study of patients with NSCLC is providing insights into their experiences and perceptions.
Certain groups continue to experience higher rates of lung cancer mortality related to chronic lower respiratory diseases.
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
The approval is for certain patients with advanced, unresectable, or metastatic NSCLC with an NRG1 gene fusion.
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
Researchers evaluated the immunogenicity and safety of the COVID-19 vaccine in patients with lung cancer.
Detailed data from the trial will be presented at a medical meeting in 2025.
The recent report shows that the "breadth of tobacco-caused disparities continues to persist and expand."
The last Surgeon General’s report on tobacco-related disparities was released more than two decades ago in 1998.
A project led by a researcher from the Dana-Farber Cancer Center is the first to receive the four-year grant of $2.5 million.
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
Researchers Analyze Olaparib, Pemetrexed as Maintenance Therapy Additions to Pembrolizumab for NSCLC
Pembrolizumab plus maintenance olaparib was not shown to improve survival in patients with metastatic nonsquamous NSCLC.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Durvalumab does not improve overall survival compared to chemotherapy when used as a first-line treatment for mNSCLC.
The updated analysis was presented at the Society for Immunotherapy in Cancer 2024 Annual Meeting.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.